

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

June 2, 2017

BSE Limited

1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: **Press Release**

Dear Sir / Madam,

We enclose herewith a copy of press release dated June 2, 2017 titled "Zydus' Moraiya Plant receives first product approval, post successful USFDA Audit."

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.


Thanking You,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**



UPEN H. SHAH
COMPANY SECRETARY



**Zydus' Moraiya Plant receives first product approval, post successful
USFDA Audit**
Receives final approval for Levofloxacin Injection

Ahmedabad, June 2, 2017

Zydus Cadila has received the final approval from the USFDA to market Levofloxacin Injection, 500 mg/20 mL and 750 mg/30 mL (25 mg/mL). Levofloxacin is used in the treatment of bacterial infections and will be produced at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

This is significant as it marks the beginning of the approval process for filings made from the Moraiya manufacturing plant after successfully completing the USFDA audit from February 6th to 15th 2017 with Zero 483 observations.

The group now has more than 115 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
